The
drug losartan may prevent lethal damage to the aorta in people with a genetic
disorder called Marfan syndrome, a preliminary study shows. The findings have
already paved the way for a large-scale trial of the drug for this condition.
“If
this observational information is backed up and confirmed by the randomized
clinical trial … it would be a tremendous breakthrough in the management of Marfan’s
syndrome,” says Alan Braverman, a cardiologist at the WashingtonUniversity in St.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.